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Abstract 
Physical activity (PA) is of key importance for health among healthy persons and individuals 
with COPD.  PA has multiple dimensions that can be assessed and quantified objectively 
using activity monitors. Moreover, as shown in the published literature, variable 
methodologies have been used to date to quantify PA among individuals with COPD, 
precluding clear comparisons of outcomes across studies. The present paper aims to provide a 
summary of the available literature for the rationale behind using objectively measured PA 
and proposes a standardized methodology for assessment, including standard operating 
procedures for future research. 
The present paper therefore describes the concept of PA, reports on the importance of PA, 
summarizes the dimensions of PA, provides a standard operating procedure how to monitor 
PA using objective assessments and describes the psychometric properties of objectively 
measured PA.  
The present international task force recommends implementation of the standard operating 
procedure for PA data collection and reporting in the future. This should allow to further clarify 
the relationship between PA and clinical outcomes, to test the impact of treatment interventions 
on PA in individuals with COPD and to successfully propose a PA endpoint for regulatory 
qualification in the future.  
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Introduction 
In 2016, the Chronic Lung Disease Biomarker & Clinical Outcome Assessment Qualification 
Consortium (CBQC) of the COPD Foundation launched an initiative to explore whether 
measures of physical activity (PA) could be qualified as efficacy endpoints or as biomarkers 
and used in clinical trials submitted to regulatory authorities [1]. PA was suggested by the 
COPD Foundation as an important end-point from the perspective of people with COPD and, 
although with less certainty, as a potential short-term surrogate for important COPD outcomes, 
such as occurrence of exacerbations and survival, that take longer than the typical study 
duration (months) to assess.   
A group of experts convened in Leuven (Belgium) with further meetings during international 
conferences of the American Thoracic Society and the European Respiratory Society to outline 
a position. After extensive review of the existing literature, the panel concluded that, while 
much effort has been made to promote objectively measured PA as a valid and responsive 
endpoint in COPD [2, 3], much uncertainty existed regarding the best methodology, monitoring 
instruments and most acceptable and accurate physical activity endpoints. This ‘white paper’ 
provides a summary for the rationale behind using objectively measured PA and proposes a 
standardized methodology for assessment, including standard operating procedures for future 
research. The task force included a global panel of key opinion leaders from the field as well 
as key industry partners conducting research in COPD with physical activity end points. By 
doing so the consortium aspires that the proposed recommendations will become widely 
adopted and pave the way to further research. This will ensure that sufficient data can be 
accumulated using standardized procedures to successfully propose a physical activity 
endpoint for regulatory qualification in the future.  
This white paper elaborates on the rationale for using PA as an endpoint in clinical trials as 
well as a proposed methodology that can be adopted in future trials to make results more 
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comparable. Whenever possible, the CBQC has pooled data from existing studies to answer 
key methodologic questions. To that end, data from the US-based COPDGene study [4] and 
the EU-based IMI-JU PROactive consortium [5] were used as well as studies from individual 
investigator members of the consortium. We propose a minimum set of data required to report 
PA as the outcome of a study. This, however, does not preclude investigators from recording 
more data in order to have a richer assessment of physical activity patterns when there is a need 
to answer specific research questions. Although this project originated from the COPD 
Foundation, a patient organisation, we acknowledge that for this specific project the consortium 
lacks a patient representative. However, several previous projects, e.g. the IMI PROactive 
project, involved patients in the study design and execution and provided information on 
patient acceptability of PA monitoring [6]. The task force has been managed by the COPD 
Foundation, acknowledging that this patient organisation considers physical activity and its 
assessment important to patients. 
The Concept of Physical Activity 
PA is defined as “any bodily movement produced by skeletal muscles resulting in an increase 
in energy expenditure of the body” [7]. It reflects the overall amount of PA undertaken by 
people. As a concept, PA is distinct from exercise capacity which relates to the ability to 
undertake PA and to the performance on tests of physical function. An individual’s PA is 
constrained by the limits of their exercise capacity, but as a behaviour it is also dependent on 
psychological, social, cultural, environmental and/or economic factors [8]. An end point model 
linking these relevant concepts is provided in Figure 1. Pharmacological and non-
pharmacological Interventions in COPD can target one or more physiological system functions 
(e.g. bronchodilators reducing expiratory flow limitation, ① in Figure 1), exercise capacity 
(e.g. exercise training, ② in Figure 1) or PA (e.g. self-management, coaching interventions, 
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policy measure to enhance PA, ③ in Figure 1). Providing detailed information on effective 
interventions to increase PA, which was recently detailed in a systematic review [9], goes 
beyond the scope of the present paper.  
In this paper, PA as a Clinical Outcome Assessment (COA) is discussed within the framework 
of the regulatory qualification requirements for novel methodologies for medicines 
development as detailed by both the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA). In this context, it is important to identify the concept of 
interest and the context of use of the COA (see below). PA biomarkers can be used as predictive 
biomarkers for prognosis. In clinical trials, PA can be used to enrich a sample for treatment 
response and/or to quantify the effect of interventions.  
The importance of PA 
In adults, lack of PA is associated with several potentially modifiable adverse outcomes and 
comorbidities. These include obesity, cardiovascular diseases, diabetes, cancer, poor mobility, 
impaired bone health, depression, cognitive impairment, impaired health-related quality of life 
and all-cause mortality [10-16]. Recent data in the general population show that better survival 
was associated with increasing activity, independent of its intensity [17, 18]. For example, in 
one study of 16741 women aged 62-101 it was found that the number of steps accumulated per 
day, rather than the intensity, was of clinical importance for mortality, with survival rates 
increasing up to approximately 7500 steps per day [18].  Difficulty participating in PA is a 
cardinal feature and consequence of COPD, occurring in the context of symptoms of 
breathlessness and fatigue. Breathlessness during PA typically drives an avoidance of PA.  
Relation to Clinically Important COPD Outcomes 
PA is related to diverse health outcomes in subjects with chronic respiratory diseases, although 
the evidence available for these is variable in amount and quality, depending on each specific 
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outcome. Higher levels of PA have consistently been related to a lower risk of acute 
exacerbations, hospitalization, and death for COPD patients [19], across different individual 
characteristics, geographic settings and instruments for measuring PA and independent of 
spirometric severity and other predictors of COPD prognosis [20]. Moreover, physical 
inactivity is likely an important contributor to much of the multi-morbidity typically observed 
in patients with COPD.  
Other important and clinically relevant end points relate to disease progression. Longitudinal 
studies are scarce, with only a few based on an objective PA assessment (summarized in Table 
1). First, many studies report a cross-sectional association between PA and lung function [19]. 
Most studies propose the hypothesis that lung function determines PA, despite several studies 
in the general population supporting bi-directionality for this association [21-23]. One recent 
study, though, found that higher PA was associated with an attenuated lung function decline in 
COPD [24]. Second, longitudinal studies in COPD show conflicting results about the relation 
between PA and exercise capacity, muscle strength or body composition outcomes, which 
might partly be explained by a difference in methodology when analysing the data and a 
difference in the observed progression in the different cohorts. It is also conceivable that 
activities of daily living, generally of low intensity, would not be associated with future 
changes in functional exercise capacity or muscle strength, which may require regularly 
scheduled intense activities. Finally, only one study investigated the relation between PA and 
progression in quality of life and found a relation with the symptom subdomain of the Saint 
George’s Respiratory Questionnaire (SGRQ) [24]. The fact that PA was not associated with 
changes in the activity domain supports the finding that the amount of PA and experienced 
difficulties with PA are distinct concepts [25]. It should be noted that trajectories for disease 
progression are very heterogenous in COPD. Therefore, longitudinal studies with repeated 
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measures of both PA and outcomes of interest as well as intervention studies using PA as a key 
outcome are needed.   
Finally, in the interpretation of the reported associations it should be taken into account that 
longitudinal data are scarce, influence of unmeasured confounding factors cannot be ruled out 
and clinical trial evidence about the effect of changing physical activity on long-term outcomes 
such as mortality is currently lacking.  
The Relevance to Patients 
The ability to participate actively in daily life is important for patients [25-27]. Patients are 
typically also able to define the concept of PA as ‘any lifestyle activity including walking, 
gardening and housework as part of their daily routine’ [28]. This definition, close to the 
operational Concept of Interest used by the CBQC working group (see below), does not single 
out one specific activity as the most relevant. Purely from a patient perspective, PA becomes 
relevant when amount, difficulty and adaptations to patients’ daily life are considered  [25]. 
Then, the experience with PA becomes an essential part of quality of life and PA limitations 
impact on the global burden of the disease. Most patient reported outcomes (PROs) assessing 
the broader concept of health status have items related to PA, reiterating the importance patients 
attribute to this concept in qualitative studies [29-31]. In addition to direct relevance to the 
patient’s experience of their disease, engaging in PA also has social, psychological, and 
physiological downstream effects.  
In summary, PA is now recognized as 1) a marker related to important endpoints that is directly 
measured under real life conditions; 2) a distinct concept that contributes to predicting 
prognosis, in addition to system and integrated physiological markers (e.g. FEV1, 6-minute 
walk test distance); 3) a measure that is understood by and directly relevant to patients as well 
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as health care providers; and 4) an outcome feasible to change, at least at the short term. As 
such, PA in COPD is an important focus of investigation and intervention.  
The Dimensions of Physical Activity  
As outlined above, PA relates to all purposeful movements of patients during the day and 
therefore includes more than sports or exercise activities. Leidy et al. [32] identified the 
following categories: household maintenance, movement, family activities, social activities, 
work, altruistic avocation, and recreation. PA is a complex behaviour, which makes it difficult 
to capture with a simple measure. Moreover, it has important day-to-day variability. Activity 
monitors provide insight into patients’ bodily movement in terms of frequency (distribution 
over the day, week), intensity (of specific movements or averaged out over the day), 
accumulated time (minutes of activity per day) and, in some cases, type (walking, cycling, 
sitting etc) of PA. When PA is objectively monitored, and data are collected in small bins (e.g. 
per minute) more granular information becomes available. For example, PA in specific 
moments may be studied, which could be relevant when interventions are expected to have 
greater effects at a specific time of the day or type of activity. 
Physical activity can be approached in several ways. One can measure the patient’s movements 
(e.g.; steps, walking time, movement intensity) or estimate energy expenditure (e.g.; active 
energy expenditure). These different concepts are explained below.  
Concepts of interest  
Overall amount of physical activity  
This concept quantifies the amount of PA performed irrespective of its intensity or duration of 
PA performed above a specific intensity threshold (e.g. time in moderate to vigorous intense 
activities). The amount of PA independent of intensity can be captured by the number of steps 
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per day. Step count is an easy-to-understand metric and it captures what is the most relevant 
and problematic daily activity for the majority of patients with COPD [33]. In the general 
population, steps per day have been used to classify people as more or less active (Table 2) 
[34]. Alternatives to total steps per day include descriptions of time spent during a specific 
activity (e.g. time in any activity, walking time, cycling time, shuffling time).  
The duration of PA performed above a specific intensity threshold quantifies the time spent 
above a threshold of PA intensity. The thresholds are set to approximately reflect the metabolic 
equivalent of tasks (METs) where 1 MET is the energy expenditure during rest [resting 
metabolic rate (RMR); typically standardized in adults to an oxygen uptake (VO2) of 3.5 
ml/min/kg body weight]. Table 3 provides intensity thresholds used to identify mild, moderate 
and vigorous exercise intensities. The thresholds can also be determined relative to the capacity 
of the patient (e.g. 50% VO2 reserve). This gives the opportunity to relate the intensity to the 
individual capacity of the patient, which is often significantly constrained. This concept gives 
an interesting insight how the capacity is constraining the patient’s activity (e.g. in the case the 
relative intensity is high despite absolute intensity being low). However, when using this 
approach, one should be cautious because it might wrongly classify those with a very low 
capacity as active when they are not [35, 36]. To the best of our knowledge, there is currently 
no clear evidence showing the added value of using individually-anchored measures of relative 
intensity when relating the physical activity to health-related outcomes. This remains an 
intriguing research question. Most guidelines advocate regular periods of PA above a threshold 
of 3 METS (i.e. Moderate to vigorous physical activity, MVPA) to maintain or improve health 
[15]. MVPA and total amount of PA (irrespective of intensity) are different outcomes but they 
are closely related in patients with COPD. Severely inactive patients will be characterized by 
low overall amount as well as low MVPA (Figure 2). Those with more severe COPD may have 
difficulties achieving physical activities with higher metabolic demand [37] and these activities 
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are the first to be reduced in early stages of the disease [38]. However, it should be noted that 
patients with COPD may consume more energy to perform the same task than a healthy 
individual of the same age and therefore MET thresholds, which are derived from healthy 
populations, may be less applicable to patients with COPD.   
Time in activities of certain intensity may be reported as total minutes or as bouts of activity 
where a given intensity is maintained.  An example might be “MVPA in bouts of at least 10 
minutes” but these bouts of uninterrupted activity are scarce among patients with COPD, 
rendering the concept less useful, especially for those with more severe COPD [37] whereas 
bouts of activities for time spent in PA at lower METs may be more relevant.  Whilst such 
bouts have been related to health benefits in the healthy population, recent evidence suggests 
that the total volume of moderate-to-vigorous PA relates to better outcomes, with no clear 
additional benefits driven by ‘bouted activity’ [39].  
Intensity of physical activity  
Intensity of PA may be reported as 1) Overall intensity of a period of time such as 1 day, or 
waking hours [e.g. mean Vector Magnitude Units (VMU) per minute; the magnitude vector of 
acceleration in three orthogonal planes]; or 2) The intensity of specific activities (e.g. 
movement intensity during walking). An interesting concept that has been introduced and 
qualified by EMA in patients with neuromuscular disease is the 95th decile of stride velocity, a 
measure of walking intensity [40]. Whether this endpoint could be of relevance in patients with 
COPD is not known.  
The amount and intensity of PA can be combined as a measure of volume of PA (e.g. total 
VMU).  
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Estimates of energy expenditure 
Human energy expenditure is highly complex and depends on a wide range of factors. Activity 
monitors estimate energy expenditure based on one or more measured parameters such as 
acceleration, heart rate or skin temperature as well as wearer-specific information such as body 
weight. Energy expenditure can be summarised, for example, as total energy expenditure or 
active energy expenditure (both in kCal or kJ). METs or Physical Activity Level (PAL), which 
can be averaged over a day, normalise the energy expenditure to resting metabolic rate, thereby 
avoiding the need to correct for individual factors such as body weight. It is important to note 
that energy expenditure related outcomes are estimates based on the modelled relation of 
acceleration and other sensor information to true energy expenditure. Although such models 
may be valid in healthy controls [41], a comprehensive validation study showed that these 
estimates lack accuracy in patients with COPD. This is partly explained by the impaired total 
efficiency and increased work of breathing in patients with lung disease [6]. 
The different concepts summarized by two factors 
To investigate whether the above-mentioned concepts are statistically distinct, a factor analysis 
including 1753 days of the baseline PA measurement of 410 patients with COPD included in 
the ‘Urban Training study’ [42] was performed.  
The factor analysis retained 2 independent factors (dimensions). Based on the contribution of 
each physical activity parameter to the two factors, measured by the coefficients (‘factor 
loadings’) in Table 4, we interpret that the two factors correspond to ‘amount of physical 
activity’ and ‘intensity of activity’. This analysis supports that the PA concepts of interests 
identified by experts and used in previous research are indeed supported by data-driven 
analysis. Interestingly and as indicated before, the measure of MVPA, which is included as a 
measure of intensity, is also related to the amount of PA in patients with COPD.“ 
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Related concepts of interest  
Patient experience of physical activity  
A different concept from objectively assessed PA is the experience patients have of PA. 
Recently the PROactive tools were developed and qualified by the European Medicines 
Agency (EMA) to assess this dimension of PA. Physical activity experience consists of two 
complementary domains: the experienced amount of PA and the experienced difficulty with 
PA [43], which match concepts recognised by patients [25].  This concept is captured by the 
PROactive tools, which were developed in line with the methodology proposed by the Food 
and Drug Administration PRO guidance [19] and properly validated in multicentre clinical 
trials using interventions likely altering experienced amount of PA (e.g., tele-coaching), or 
experienced difficulty with PA (e.g., bronchodilators) or both (e.g., rehabilitation) [44]. The 
PROactive tools provide insight in how patients experience physical activity, rather than 
capturing how much physical activity is effectively performed and the intensity thereof, which 
is likely more related to physiologic or health outcomes.  
Symptoms experienced during physical activity 
Several questionnaires aim to investigate the symptoms patients with COPD experience during 
PA. Common symptoms include shortness of breath, fatigue, pain and sometimes anxiety 
(fear). These are beyond the scope of this review and details are provided in a systematic review 
[45].   
Sedentary behaviour 
Sedentary behaviour has been defined as ‘any waking behaviour characterized by an energy 
expenditure of <1.5 MET in a sitting or reclining posture’. In the healthy population sedentary 
behaviour and PA are clear distinct concepts, with an independent relation to mortality [46]. In 
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other words, a high physical activity level does not mean one has a low sedentary time and 
both behaviours have prognostic value. One paper also suggested this independent association 
of sedentary behaviour and physical activity with mortality in patients with COPD [47]. 
However, other papers have shown that sedentary time and physical activity are strongly 
negatively related  [24, 48]. In other words, in patients with COPD, a higher physical activity 
is accompanied with lower sedentary time and changing one behaviour might result in a change 
in the other. This stronger association can likely be explained by the narrower spectrum in 
physical activity patients present with. However, more research on sedentary behaviour in 
patients with COPD is needed. Whether our recommendations to measure physical activity are 
also appropriate to measure sedentary behaviour is not yet clear. However, these discussions 
go beyond the scope of the present paper, which is focused on objectively measured PA. 
How to monitor physical activity objectively. 
It is generally accepted that PA measured by questionnaires can be used to categorize patients 
in large epidemiological studies. Objective measurements have become more feasible as 
technology advances. An objective assessment is needed when the aim is to provide a directly 
measured and accurate assessment of an individual patients’ PA pattern within a clinical trial. 
As currently no standardized methodology exists to assess and process PA data [9], we aim to 
provide rationale for a standardized approach in the next paragraphs. We will focus only on 
objective measurement of PA using activity monitors in patients with no apparent locomotor 
impairments (e.g.; tremor).  
Types of monitoring devices 
Currently, PA is most effectively assessed in daily living using small, unobtrusive PA monitors. 
Micro Electromechanical Systems (MEMS), e.g., accelerometers, gyroscopes and pressure 
sensors, can objectively and accurately quantify movements and the context of the movements 
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(e.g. stair climbing with differences in altitude) under controlled as well as free living 
conditions. The complexity of the monitor drives its use. Step counters, for example, provide 
only step counts often without time stamps and may suffice for feedback to the user as part of 
behavioral interventions [49]. Other activity monitors provide more detail on quantity and 
quality of activities and may be more appropriate for outcome measurements for clinical trials. 
Activity monitors may be used in conjunction with positioning systems (although this raises 
potential privacy issues) and physiological sensors (e.g., heart rate, skin temperature). 
Integration of data can potentially increase the accuracy of estimated PA and energy 
expenditure. Whether these combinations will lead to clinically relevant improvements over 
existing algorithms needs to be confirmed [50].  
Consumer vs. medical grade monitors 
Figure 3 provides a comparison of consumer and medical grade monitors. Devices included in 
interventional clinical trials, especially phase 3 or later studies, are subject to greater regulatory 
requirements and scrutiny than monitors that are used personally, in the clinic or for 
observational studies. Specifically, interventional clinical trial considerations within the 
pharmaceutical industry require devices not only to meet requirements associated with a 
medical-grade CE mark and/or 510(k) approval in the EU and US respectively, but also to 
provide full audit trails to demonstrate data integrity, security and privacy throughout the signal 
chain from initial data collection through long-term storage; this makes such devices 
considerably more expensive [51, 52]. Activity monitors that store raw data require more 
sophisticated signal processing after data collection and can detect detailed patterns of PA. 
They can be more sensitive and accurate in detection of motion even in less active individuals. 
Size of the device depends on the intended use. For example, if the intended use does not allow 
intermittent charging, a larger battery and hence a larger casing is needed. Similarly, 
continuously storing raw data including time stamps increases energy consumption of the 
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device and hence the size of the battery, which in turn may impact wearability and adherence 
over longer periods of time.  
Observational, clinical and personal use of monitors, however, do not necessitate the use of 
medical research grade devices. Alternative devices are commercially available for these 
purposes that can bring additional features, reduced size and/or reduced cost. Due to the 
complex requirements of patient safety, data integrity, security and privacy, medical grade 
devices together with secure data servers may be preferable for use in multi-site interventional 
clinical trials, but these requirements may be different for an observational study, or for routine 
clinical or personal use.  
Consideration of the intent of the PA measurement within a clinical trial is also important. 
Some devices give direct feedback to the study participant (e.g. step counts or sensory cues to 
increase activity), and therefore are useful if the intention is to intervene on the participant’s 
normal PA patterns. Typically, medical grade devices are “closed”, meaning that they are 
designed to be inobtrusive as possible to the participant and therefore assess normal 
spontaneous PA during an observational trial or in response to study drug, device or 
behavioural intervention. 
Sampling and Algorithms 
The sampling rates and (often proprietary) algorithms used to generate outputs can also vary 
greatly between devices, making comparisons across devices difficult. Even medical-grade PA 
monitors employ different step-detection strategies, which impact on outputs, even for steps 
per day [53]. Therefore, for repeated measures patients should be measured with the same type 
of device. In addition, comparison of different populations is more accurate if the same device 
has been used. For clinical trial purposes, the FDA has indicated through the Clinical Trials 
Transformation Initiative (CTTI) that consideration of any PA outcome should be device 
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agnostic however device sensitivity and accuracy as well as data verification and 
documentation of validity remain critical considerations [54]. Higher sampling rates can 
capture faster movements but require more data storage and may reduce battery life so 
sampling rate should be carefully balanced with study needs including transmission and storage 
of the data volume. 
Validity 
The validity of activity monitors to detect PA in patients with COPD has been the subject of 
several recent studies. In 2012 and 2014, the IMI PROactive consortium published a 
methodologic standard for validation of activity monitors using a ‘lab based’ (validation 
against indirect calorimetry using a portable metabolic system)  [55] and a ‘real life’ approach 
(validation against doubly labelled water indirect calorimetry) [6]. This consortium found that 
the DynaPort MoveMonitor (McRoberts BV, the Hague, the Netherlands), the Actigraph 
GT3X (Actigraph, Pensacola, FL, USA) and the SenseWear Armband (BodyMedia, Inc., 
Pittsburgh, PA, USA) (each employing bi- or tri-axial MEMS accelerometers) were valid and 
responsive for use in patients with COPD. These activity monitors showed similar properties 
in studies performed by other research groups [56]. Other medical grade devices have been 
validated as well. One example is the StepWatch Activity Monitor (an ankle-worn 
accelerometer) which has been validated in a lab based approach (validation against manual 
step count) in a US COPD cohort [57]. Newer consumer devices (wearables) are available, 
such as Fitbit devices and Polar Watches as well as medical devices such as Philips Health 
watch, Apple Watch Series 4 and Verily Study Watch. These sensors are more user-friendly 
and are preferred by patients but lack accuracy [58]; we would therefore recommend testing 
the relative accuracy in a representative COPD population prior to using any new device. In 
general, wrist worn monitors tend to have lower accuracy for step counts compared to monitors 
worn closer to the centre of body mass (e.g., on the belt) [59].  
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Recommendations for Standard Operating Procedure for Data Collection 
A wide variability in PA measurement methodology is present in the existing literature [9]. 
The way PA data are collected and processed after collection (post processing) has an impact 
on the psychometric properties of the outcome. The CBQC therefore recommends that a 
standard operating procedure be used for data collection regarding the outcome of PA. A 
standardized methodology may guide investigators to obtain a more precise and robust 
outcome and would enable comparisons of outcomes to be made across studies. Several 
methodological aspects should be considered. While these decisions may vary depending on 
the aim of the assessment and the included population, or can be changed to answer a specific 
research question, it is an important aim of this white paper to make suggestions for 
standardization of the assessments. The recommendations provided in the present paper apply 
to PA assessments in stable patients with COPD, focusing on the assessment of overall PA. An 
overview of the recommendations is provided in Table 5. Further discussion of each 
recommendation is provided below.  
Measurement interval 
To date, the most commonly used measurement intervals for PA assessment are “24-hours” or 
“during waking hours”. Patients with COPD typically perform most activity between 7AM and 
10PM [60-63], across different centres in different countries (Figure 4). Although the PA 
pattern varies throughout the day among patients measured in different parts of Europe, patients 
across the different centres have on average taken 95% of their total daily steps by 10PM. This 
timeframe is not different from the PA pattern of a population based cohort with comparable 
age [64] and does not differ between seasons [61] or across disease severity [62]. When using 
the total amount of PA as the outcome (e.g. steps, total time in activity), a restriction of the 
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sample interval to daytime hours will not noticeably influence the outcome. However, when 
using a measure of average intensity (e.g. Vector magnitude units/min), including the sleep 
period will considerably affect the outcome. This is because including sleep period hours, the 
calculated average per minute will include many hours where PA is at or close to resting, rather 
than reflecting the average per minute VMU during hours where PA is more likely to occur. 
Variation in sleeping time, therefore has the potential to affect daytime VMU/min calculated, 
if included within the assessment interval. To optimize the adherence of patients to wearing 
the device, lower the burden and to standardize the sampling interval, we recommend a 
measurement during waking hours to measure physical activity. If a 24 hour assessment is 
performed, it is advised to standardize the sampling interval for PA assessment towards an 
assessment of waking time, based on a subject’s own sleeping time or using the hours between 
7AM and 10PM. The rest of the collected data can be relevant to assess sleep related outcomes. 
When patients work night shifts these hours need to be adjusted.  
Assessment duration 
Rabinovich, et al. [6] showed that almost the entire sample of patients with COPD would be 
willing to wear an accelerometer for at least one week . Several other studies in COPD, and at 
the population level, were successful in recording almost 7 days [4, 5, 42, 64]. By asking 
patients to wear the monitor for 1 week, there is a high likelihood that a sufficient number of 
valid days is obtained to be used in statistical analyses (see further discussion below). 
Moreover, data collected in COPDGene study showed a strong week-by-week correlations 
based on 3 weeks assessment, supporting the need to only measure one week in stable patients 
[4].  Whereas it is sometimes argued that the measurement itself may influence PA behaviour 
of patients (Hawthorne effect), this has never been convincingly shown in patients with COPD. 
In figure 5, we show data of 151 COPDGene participants with PA data collected on 21 
consecutive days [4]. No differences were found between the first and later days, arguing 
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against a Hawthorne effect. This could be explained by the lack of direct feedback provided by 
the monitor, as discussed before. It is not advised that the day of a clinical visit is part of the 
assessment as this does not represent a normal day for the patient’s behaviour. 
 
Measurement instructions 
As per expert opinion, subjects are best instructed in person how to use the monitor, according 
to the manufacturer’s guidance. Study site staff (where applicable) should be familiarized with 
the device ahead of trial recruitment, and there should be emphasis on instructing subjects to 
adhere to the recommended wear time. Ideally, monitors should require minimal instructions 
in order to obtain a valid measurement. Instructions may be provided by a written instruction 
sheet, demonstration and/or video [65]. This includes i) Information about the correct 
positioning of the monitor; ii) The measurement interval (e.g., start wearing from the moment 
you wake up until the moment you go to bed at night), with specific instructions to keep 
wearing the device throughout the day, including during sedentary behaviours or when feeling 
ill; iii) Instructions when to take off the monitor (usually during water activities, bathing and 
showering);  iv) Start and stop date of the assessment; and v) Any other instructions such as 
how and how often to charge the device (if required).  
Logbook 
A logbook may be useful to interpret individual patient data. In this log book patients can i) 
record the start and end of waking hours; ii) note the period(s) of taking off the monitor during 
the day and the water activities where the monitor has been taken off, mostly if they involve 
PA (e.g., swimming) and iii) report changes in health status. Based on this logbook, adherence 
of the patient to the data collection instructions can be verified. The logbook can be paper, 
website or application based.  
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Processing of data and standardisation of statistical analyses 
Data analytics for wearable sensors typically go through several steps, as depicted in Figure 6. 
Each step in the signal chain needs to be thoroughly thought out and tested.  
Algorithms and data reduction 
Each single subject’s raw sensor data are processed through algorithms to convert them into a 
meaningful time series prior to generating outcomes that are useful to investigators, clinicians 
and/or patients. These algorithms will have an important role in filtering artefactual activity 
(e.g. sitting in a car) from real activity. Typically, data are first reduced by algorithms from 
multiple points per second to a less granular level such as minute-by-minute or day-by-day. 
Various studies have tested activity monitors and the algorithms provided by manufacturers in 
order to determine their accuracy in a COPD population [6, 55]. Some medical-grade devices 
store raw data, enabling a researcher to go back to the raw data and apply or develop the most 
appropriate algorithms and settings, even applying new algorithms developed after the data 
were collected. This allows researchers greater flexibility in creating “specific measurements” 
that are considered to be relevant. Many different features are reported in the literature, ranging 
from simple concepts such as total steps per day to more complex constructs such as duration 
and intensity of bouts of PA. This area has previously been reviewed [66] and was presented 
earlier in this paper. An important development for the future could be to derive device-
agnostic algorithms that allow open source data reduction in order to enable better comparisons 
between different devices. Currently a European Innovative Medicine’s Initiative (IMI) project 
is attempting to develop such algorithms www.mobilise-d.eu. 
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Statistical interpretation of the sensor data 
Daily patient-level measurements are then further analysed by statisticians or researchers, who 
generate an interpretable patient-, group- and cohort-level output. This work must take several 
steps into account, as described below. 
a) Definition of a valid day of assessment  
Validating the assessment based on the wearing time is of utmost importance to ensure that the 
variables obtained are representative of patient’s actual daily PA. Insufficient wearing time will 
result in a lower total amount of PA or an incorrect measure of average PA intensity. Including 
night-time data lowers average daily measures, as discussed above. Wearing time criteria 
should balance representative PA assessment against excluding too many days due to too 
stringent criteria for the present population. Among patients with COPD the use of at least 8 
hours of wearing time during waking hours was previously recommended [60]. PA assessment 
may be done over 24 hours, but it is recommended that a valid day is defined as having at least 
8 hours of daytime wearing time in the standardized time frame between 7AM and 10PM 
(Figure 7). Where possible one can adjust these times considering individuals’ own sleep 
patterns, as determined from the data and ideally verified using the subject logbook or from 
algorithms if they can reliably detect overnight sleeping and waking moments. Of note, patients 
should always be asked to wear the monitor during all hours, except for water-based activities, 
which will normally result in more than 8 hours of wearing time.  
 
b) Weekday vs. weekend days 
PA measures during the weekend are typically lower than those obtained during weekdays 
among individuals with COPD [6, 67] and across populations (Figure 8). However, the pattern 
of PA tends to be similar on weekends and weekdays [62]. Importantly, data shows that adding 
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weekend days increases variability, but not the observed effect, of the outcome measure. In an 
interventional design, this resulted in an increase in the sample size needed to obtain a given 
statistical power [60]. Therefore, when aiming to use the obtained variable as an endpoint in a 
clinical trial, one can consider exclusion of weekend days in the PA outcome in order to lower 
variability and required sample size to identify a specified interventional effect. If the aim of 
the measurement is to fully characterize PA of a patient cohort, both weekdays and weekend 
days are recommended to use in the calculation (see step 3 Figure 7). To be able to compare 
baseline characteristics across studies we propose to always report baseline characteristics of 
the tested population including all measured days. It needs to be recognised, however, that 
these recommendations are based on a limited number of studies and of limited disease severity 
and geographic variability, so further research is needed to revise these criteria in other settings.  
 
c) Number of valid days required  
As above, we recommend asking patients to wear the monitor for 1 week, to ensure a high 
likelihood that a sufficient number of valid days is obtained to be used in statistical analyses.  
When only weekdays are included, a reliable assessment may be obtained based on at least 2 
weekdays [60, 63]. When combining weekdays and weekend days, Watz et al. [67] concluded 
that 2–3 days was sufficient for a reliable PA assessment in patients with GOLD stage IV but 
that 5 days of measurement were needed in patients with GOLD stage I. During periods when 
typical PA is disturbed (e.g. acute exacerbation), fewer days of assessment can be sufficient to 
identify abnormal PA [68]. When the aim is to use PA as an endpoint in an interventional trial, 
Demeyer et al. [60] showed that including more weekdays (up to 4) resulted in a decreased 
variability of the outcome measure.  
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As a result, having more weekdays (up to 4) in the measurement will decrease the sample size 
required to obtain an appropriate statistical power. Therefore, when used in clinical trials, one 
should aim to obtain 4 complete (week)days in the PA assessment which can be considered as 
the ‘ideal recommended situation’ (Figure 7). These 4 days need not to be consecutive. Since 
adherence to wearing activity monitors is an important issue, more days of assessment might 
lead to a loss of patients in the sample due to imperfect adherence, especially in studies with 
multiple measurements (Figure 9). Therefore, since it is still a reliable assessment, the minimal 
required number of days to maintain a single patient visit in the analysis can be as low as two 
weekdays (Figure 7).  
 
The day-by-day data that meet the above described acceptability criteria are then summarized 
into a mean daily PA assessment per patient to use for cohort-level statistical analyses. Of note, 
this mean should be based on all existing valid days (e.g., in the case of an assessment of 5 
valid days, which is judged valid as the number of days if more than 2, the mean will be 
calculated based on the 5 available data points), see Figure 7. It is important to know that 
several external factors can impact the data, including weather, time of year, individuals’ 
routines, occupation and social and psychological effects [69, 70]. These can be important 
covariates, so it is recommended to minimise their impact on the variability of the specific 
measurement wherever possible and to take these effects into account during statistical 
interpretation [60].  
Standardization of Reporting  
In all cases, all of the components of PA measurement and post-processing of data discussed 
above should be reported in the methods of reports describing PA in a COPD population. This 
includes information about data collection (sampling period, number of days, instructions to 
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patients), the algorithms used (if applicable), data reduction and statistical interpretation 
(including definition of a valid day based on the wearing time, type of days and number of days 
included in the summarized outcome).  
As an example:  
Methods - “Patients were asked to wear the [manufacturer] [device name] [device version] 
activity monitor for 7 consecutive days. They were instructed to wear the monitor from the 
moment they woke up until the moment they went to sleep. Patients were asked to note in a 
logbook when the monitor was not worn during the waking hours of the assessment period for 
quality control. Day-by-day data were exported using the company’s algorithms ([software 
name] [version xx]) to retrieve wearing time, steps per day and time in at least moderate intense 
activity with settings [yy] and [zz]. All valid days (at least 8 hours of wear time in each) were 
included in the analyses. A PA assessment was judged adequate and representative if it 
included at least 4 valid days”.   
Results- “From a total of [x] patients, [x] were excluded because they did not fulfil the criteria 
of at least valid 4 days of at least 8 hours’ wear time. Among the included patients, mean (SD) 
of wearing days was [x (SD)] and mean wearing time was [x (SD)].   
Psychometric properties of physical activity  
Reliability and sensitivity of end points 
Reliability (i.e., the ability to produce similar results under consistent conditions) is challenging 
to assess in real life, as PA has a large inherent day-to-day variability within a subject. 
Therefore, the assessment of a patient’s PA as a concept becomes more ‘reliable’ when more 
assessment days are combined (as discussed above). Of note, among patients with less severe 
disease, the statistical reliability seems lower, as the day-to-day variability in PA is larger in 
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these patients. However, in a test-retest based on 2 consecutive weeks of PA assessment, 
reliability was high (ICC 0.93) [71]. It is concluded that contemporary PA monitors reliably 
assess PA, but that the concept of an individual’s PA may be inherently more variable than 
measures such as exercise capacity or lung function.  
The sensitivity of a test to identify change due to clinical interventions is linked to both the 
effect of the interventions on the outcome as well as the reliability of the outcome measure. 
This is captured by the standardized response means (SRM; mean Δ/SD Δ). Demeyer et al. 
showed that the SRM (for an identical intervention) was greater when more days of assessment 
are included and when weekends were excluded from the analysis [60]. The main reason was 
a reduction in standard deviation, rather than differences in effects. In addition, these authors 
showed that using daily step count as an outcome resulted in greater SRM compared to other 
activity monitor outcomes tested (e.g. time in at least moderate intense activity, or mean METs 
as outcome measures), meaning that daily step count was a more sensitive endpoint than the 
other measures tested in that study. 
The minimal important difference 
Assessment of the minimal important difference (MID) is a standard method to interpret 
whether or not an intervention effect is clinically meaningful. The availability of a MID also 
allows the presentation of ‘responder analyses’ and is a basis for sample size calculations. The 
aim of the MID is to reflect both a minimally important difference between groups (such as 
derived from distribution based-methods) and a minimally important difference or response 
within an individual over time (such as derived from anchor-based methods). Therefore, a 
frequently used approach to estimate a MID is combining anchor-based and distribution-based 
methods and to triangulate a single value or small range of values for the MID. The MID in PA 
for patients with COPD has been described only in two studies [71, 72]. Both studies targeted 
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daily steps as the PA endpoint, used triangulated anchor-based methods combining a clinical 
indicator with distribution-based methods and resulted in similar MID estimations (600 to 1100 
steps [71] and 350 to 1100 steps [72]). One study was conducted in an outpatient pulmonary 
rehabilitation setting and used the beneficial effect of pulmonary rehabilitation on PA and 
hospital readmission to estimate the MID of increased PA [71], the other one used the negative 
effect of clinically significant medical events (i.e., acute exacerbations or hospital admission) 
to assess the MID of decreased PA [72]. Hence, the MID seems to coincide with important 
clinical outcomes (Minimal clinical important difference, MCID). In light of the biomarker 
qualification process it is important to note that none of the MID estimations currently available 
were derived in the context of a drug intervention. Because the MID is population specific and 
estimated of MIDs that have been obtained from pulmonary rehabilitation studies, do not 
necessarily directly translate to drug interventions, more research is needed in this area. Of 
note, recently the MID for the PROactive tool, which measures physical activity from the 
patient perspective, has been estimated to be 6 for amount and difficulty scores and 4 for the 
total score [44]. 
Expectations of Regulatory authorities 
To be accepted in the context of a ‘labelling claim’ request (e.g. “in patients with moderate to 
severe COPD, product [xxx] was shown to improve PA”) any outcome measure used needs to 
be either already established as valid or to be developed appropriately prior to undergoing a 
thorough qualification process as detailed in EMA [73] and FDA guidance [74].  An important 
prerequisite is to define the context of use (CoU), which is a critical element for the regulatory 
assessment of any qualification application. This specifies the specific use of the instrument, 
e.g. digital biomarker, in the drug development process. For the FDA the CoU provides the 
boundaries within which the biomarker (e.g. steps per day) may be adequately used.  
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As an example, based on current knowledge, we would propose the following CoU for physical 
activity:  
Biomarkers of overall physical activity, such as steps per day, are valid, reliable and sensitive 
endpoints to evaluate efficacy of pharmacological and non-pharmacological interventions in 
patients with chronic obstructive pulmonary disease (COPD). 
Over time the CoU may be extended as more data become available.  Table 6 provides the 
outstanding questions for which data are needed to support a biomarker for a given CoU. 
The use of digital tools (e.g. activity monitors) to capture PA complicates the regulatory 
process as, at present, devices are not interchangeable and technical and regulatory 
requirements in the different jurisdictions need to be met (e.g., the 2017 EU Medical Device 
Regulation [51]). Requirement criteria relate to 1) the safety, usability and acceptability of the 
device for patients with COPD. For activity monitors there are data to suggest that these criteria 
are met [6]. 2) the device produces reliable and accurate data (see above); and 3) in clinical 
trials and in accordance with its CoU, a specific device needs to be approved or cleared by 
regulatory authorities as detailed by the FDA [52] or through other existing recommendations 
[54] or more recently [75].  
In summary, this group of experts is of the opinion that regulatory agencies may be willing to 
consider PA endpoints (e.g. steps per day or other) to support labelling claims around 
engagement in PA in COPD, if they are used as secondary endpoints, employ validated sensors 
and use the recommendations detailed in this paper. Currently steps per day carries the largest 
clinical evidence across a spectrum of interventions and COPD populations. It meets most - if 
not all – criteria required for qualification. Other, less frequently used, endpoints also have 
potential, particularly those that capture PA intensity or PA characteristics not captured by 
measurements of steps per day. So far, only physical activity experience has been recognised 
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by regulators for labelling claims of drugs in COPD [76]. As outlined above, this is a different, 
patient reported outcome.  
 
Conclusion 
Physical activity is of key importance for health and clinical outcomes among healthy persons 
and individuals with COPD. PA has multiple dimensions that can be assessed and quantified 
objectively using activity monitors. Variable methodologies used in the existing literature to 
date to quantify PA among individuals with COPD precludes clear comparisons of outcomes 
across studies and hinders incorporation of PA as clinical trial outcome by regulatory agencies 
such as the FDA and EMA. The CBQC of the COPD Foundation recommends implementation 
of a standard operating procedure for PA data collection and reporting, that should, over time, 
further clarify the relationship between PA and clinical outcomes, the impact of treatment 
interventions on PA, and enable use of PA endpoints to support labelling claims around 
engagement in PA in COPD. 
  
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
Acknowledgements 
The authors would like to acknowledge the COPD foundation for their support in the 
organization of the meetings. We would like to acknowledge John W Walsh (†March 7th 
2017) for his inspiring support in the initiation of the project.  
Author Contributions 
All authors were involved in data review and interpretation, were involved at all stages of 
manuscript development, writing and revision, approved the final manuscript and agree to be 
held accountable for all aspects of the work.  
Data Sharing Statement 
Data presented in the present manuscript can be made available upon request.  
Declaration of Interest 
Dr. Heleen. Demeyer is a post-doctoral research fellow of FWO Flanders; Drs.Divya Mohan 
and Ruth Tal-Singer are former employees and current shareholders of GSK; Dr. Tal-Singer 
reports personal fees from Immunomet, and Vocalis Health. Dr. Mohan is a current employee 
of Genentech; Matthew Heasley is a full time employee and shareholder at GlaxoSmithKline; 
Dr. Richard Casaburi reports personal fees from Astra Zeneca, Boehringer Ingelheim, Glaxo 
SmithKline, Genentech, Respinova and Regeneron; Dr. Christopher Cooper reports grants 
from NIH/NHLBI, Foundation NIH and COPD Foundation during the conduct of the study. 
He also reports personal fees from PulmonX, GlaxoSmithKline, NUVAIRA and MGC 
Diagnostics, outside the submitted work; Dr. Stephen Rennard was employed by AstraZeneca 
and holds shares; Dr. Alan Hamilton is an employee of Boehringer Ingelheim (Canada) Ltd; 
Niklas Karlsson is employed by AstraZeneca; Dr. William Man reports grants from National 
Institute for Health Research; grants from British Lung Foundation, personal fees from Jazz 
Pharmaceuticals, personal fees from Mundipharma, personal fees from Novartis, non-financial 
support from GSK, grants from Pfizer, outside the submitted work; Dr. Michael Polkey is a 
paid consultant for Philips Respironics, JFD and has received fees for lecturing from Genzyme 
Sanofi, GSK.  His institution has received fees for research from GSK and Novartis, relating 
to Dr. Polkey’s work; Dr. Carolyn Rochester participates in clinical trials sponsored by Astra-
Zeneca, and has received personal fees for scientific advisory board participation from Glaxo 
SmithKline and Boehringer Ingelheim; Dr. Henrik Watz. received payments for 
lectures/consulting honorarium/travel support from Almirall, AstraZeneca, BerlinChemie, 
Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, Novartis and received unrestricted 
research grants from AstraZeneca and GlaxoSmithKline; the employer of Dr. Watz (Pulmonary 
Research Institute at LungenClinic Groshansdorf) received compensation for participation in 
clinical trials and consulting fees from Almirall, Takeda,AstraZeneca, Boehringer Ingelheim, 
GlaxoSmithKline, Merck, Novartis, Pfizer, TEVA, Bayer HealthCare, Revotar, Sterna, Roche, 
AB2BIO, Philips; Dr. Martijn Spruit reports grants from Netherlands Lung Foundation, grants 
from Stichting Astma Bestrijding, grants and personal fees from AstraZeneca, grants and 
personal fees from Boehringer Ingeheim, all outside the submitted work; Dr. Judith Garcia-
Aymerich reports other from AstraZeneca, other from Chiesi, outside the submitted work; Dr. 
Thierry Trooster’s institute received speaker/consultancy fees on the topic of physical activity 
from BI, AZ, Chiesi and Bayer; Other authors have nothing to disclose relevant to the submitted 
work.  
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
References 
1. Casaburi, R., et al., The COPD Biomarker Qualification Consortium (CBQC). COPD, 
2013. 10(3): p. 367-77. 
2. Troosters, T., et al., Improving physical activity in COPD: towards a new paradigm. 
Respir Res, 2013. 14: p. 115. 
3. Watz, H., et al., An official European Respiratory Society statement on physical 
activity in COPD. Eur Respir J, 2014. 44(6): p. 1521-37. 
4. Bowler, R., et al., Real-world use of rescue inhaler sensors, electronic symptom 
questionnaires and physical activity monitors in COPD. BMJ Open Respir Res, 2019. 
6(1): p. e000350. 
5. Demeyer, H., et al., Physical activity is increased by a 12-week semiautomated 
telecoaching programme in patients with COPD: a multicentre randomised 
controlled trial. Thorax, 2017. 72(5): p. 415-423. 
6. Rabinovich, R.A., et al., Validity of physical activity monitors during daily life in 
patients with COPD. Eur Respir J, 2013. 42(5): p. 1205-15. 
7. Caspersen, C.J., K.E. Powell, and G.M. Christenson, Physical activity, exercise, and 
physical fitness: definitions and distinctions for health-related research. Public Health 
Rep, 1985. 100(2): p. 126-31. 
8. Bauman, A.E., et al., Correlates of physical activity: why are some people physically 
active and others not? Lancet, 2012. 380(9838): p. 258-71. 
9. Burtin, C., Objective physical activity as a clinical trial outcomes in patients with 
COPD: a systematic review of the literature by a Task Force of experts on physical 
activity in COPD. submitted. 
10. Blair, S.N., et al., Physical fitness and all-cause mortality. A prospective study of 
healthy men and women. JAMA, 1989. 262(17): p. 2395-401. 
11. Larson, E.B., et al., Exercise is associated with reduced risk for incident dementia 
among persons 65 years of age and older. Ann Intern Med, 2006. 144(2): p. 73-81. 
12. Lee, I.M., et al., Effect of physical inactivity on major non-communicable diseases 
worldwide: an analysis of burden of disease and life expectancy. Lancet, 2012. 
380(9838): p. 219-29. 
13. Moore, S.C., et al., Association of Leisure-Time Physical Activity With Risk of 26 
Types of Cancer in 1.44 Million Adults. JAMA Intern Med, 2016. 176(6): p. 816-25. 
14. Mozaffarian, D., et al., Physical activity and incidence of atrial fibrillation in older 
adults: the cardiovascular health study. Circulation, 2008. 118(8): p. 800-7. 
15. Piercy, K.L., et al., The Physical Activity Guidelines for Americans. JAMA, 2018. 
320(19): p. 2020-2028. 
16. Sallis, J.F., et al., Progress in physical activity over the Olympic quadrennium. 
Lancet, 2016. 388(10051): p. 1325-36. 
17. Ekelund, U., et al., Dose-response associations between accelerometry measured 
physical activity and sedentary time and all cause mortality: systematic review and 
harmonised meta-analysis. BMJ, 2019. 366: p. l4570. 
18. Lee, I.M., et al., Association of Step Volume and Intensity With All-Cause Mortality in 
Older Women. JAMA Intern Med, 2019. 
19. Gimeno-Santos, E., et al., Determinants and outcomes of physical activity in patients 
with COPD: a systematic review. Thorax, 2014. 69(8): p. 731-9. 
20. Waschki, B., et al., Physical activity is the strongest predictor of all-cause mortality 
in patients with COPD: a prospective cohort study. Chest, 2011. 140(2): p. 331-342. 
21. Fuertes, E., et al., Leisure-time vigorous physical activity is associated with better 
lung function: the prospective ECRHS study. Thorax, 2018. 73(4): p. 376-384. 
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
22. Garcia-Aymerich, J., et al., Regular physical activity modifies smoking-related lung 
function decline and reduces risk of chronic obstructive pulmonary disease: a 
population-based cohort study. Am J Respir Crit Care Med, 2007. 175(5): p. 458-63. 
23. Hopkinson, N.S. and M.I. Polkey, Does physical inactivity cause chronic obstructive 
pulmonary disease? Clin Sci (Lond), 2010. 118(9): p. 565-72. 
24. Demeyer, H., et al., Physical Activity Is Associated with Attenuated Disease 
Progression in Chronic Obstructive Pulmonary Disease. Med Sci Sports Exerc, 2019. 
51(5): p. 833-840. 
25. Dobbels, F., et al., The PROactive innovative conceptual framework on physical 
activity. Eur Respir J, 2014. 44(5): p. 1223-33. 
26. Gardiner, C., et al., Exploring the care needs of patients with advanced COPD: an 
overview of the literature. Respir Med, 2010. 104(2): p. 159-65. 
27. Hogg, L., et al., People with COPD perceive ongoing, structured and socially 
supportive exercise opportunities to be important for maintaining an active lifestyle 
following pulmonary rehabilitation: a qualitative study. J Physiother, 2012. 58(3): p. 
189-95. 
28. Kosteli, M.C., et al., Barriers and enablers of physical activity engagement for 
patients with COPD in primary care. Int J Chron Obstruct Pulmon Dis, 2017. 12: p. 
1019-1031. 
29. Williams, K., et al., Patient-reported physical activity questionnaires: a systematic 
review of content and format. Health Qual Life Outcomes, 2012. 10: p. 28. 
30. Jones, P., et al., Improving the process and outcome of care in COPD: development of 
a standardised assessment tool. Prim Care Respir J, 2009. 18(3): p. 208-15. 
31. van der Molen, T., et al., Development, validity and responsiveness of the Clinical 
COPD Questionnaire. Health Qual Life Outcomes, 2003. 1: p. 13. 
32. Leidy, N.K. and J.E. Haase, Functional performance in people with chronic 
obstructive pulmonary disease: a qualitative analysis. ANS Adv Nurs Sci, 1996. 
18(3): p. 77-89. 
33. Annegarn, J., et al., Problematic activities of daily life are weakly associated with 
clinical characteristics in COPD. J Am Med Dir Assoc, 2012. 13(3): p. 284-90. 
34. Tudor-Locke, C., et al., A step-defined sedentary lifestyle index: <5000 steps/day. 
Appl Physiol Nutr Metab, 2013. 38(2): p. 100-14. 
35. van Remoortel, H., et al., Moderate intense physical activity depends on selected 
Metabolic Equivalent of Task (MET) cut-off and type of data analysis. PLoS One, 
2013. 8(12): p. e84365. 
36. Hartman, J.E., et al., Physical activity recommendations in patients with chronic 
obstructive pulmonary disease. Respiration, 2014. 88(2): p. 92-100. 
37. Donaire-Gonzalez, D., et al., Physical activity in COPD patients: patterns and bouts. 
Eur Respir J, 2013. 42(4): p. 993-1002. 
38. Van Remoortel, H., et al., Daily physical activity in subjects with newly diagnosed 
COPD. Thorax, 2013. 68(10): p. 962-3. 
39. Saint-Maurice, P.F., et al., Moderate-to-Vigorous Physical Activity and All-Cause 
Mortality: Do Bouts Matter? J Am Heart Assoc, 2018. 7(6). 
40. Haberkamp, M., et al., European regulators' views on a wearable-derived 
performance measurement of ambulation for Duchenne muscular dystrophy 
regulatory trials. Neuromuscul Disord, 2019. 29(7): p. 514-516. 
41. Sirichana, W., et al., Wrist-worn triaxial accelerometry predicts the energy 
expenditure of non-vigorous daily physical activities. J Sci Med Sport, 2017. 20(8): p. 
761-765. 
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
42. Arbillaga-Etxarri, A., et al., Long-term efficacy and effectiveness of a behavioural and 
community-based exercise intervention (Urban Training) to increase physical activity 
in patients with COPD: a randomised controlled trial. Eur Respir J, 2018. 52(4). 
43. Gimeno-Santos, E., et al., The PROactive instruments to measure physical activity in 
patients with chronic obstructive pulmonary disease. Eur Respir J, 2015. 46(4): p. 
988-1000. 
44. Garcia-Aymerich, J., et al., Validity and responsiveness of the Daily- and Clinical 
visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments. 
Thorax, 2021. 76(3): p. 228-238. 
45. Frei, A., et al., A comprehensive systematic review of the development process of 104 
patient-reported outcomes (PROs) for physical activity in chronically ill and elderly 
people. Health Qual Life Outcomes, 2011. 9: p. 116. 
46. Ekelund, U., et al., Does physical activity attenuate, or even eliminate, the detrimental 
association of sitting time with mortality? A harmonised meta-analysis of data from 
more than 1 million men and women. Lancet, 2016. 388(10051): p. 1302-10. 
47. Furlanetto, K.C., et al., Sedentary Behavior Is an Independent Predictor of Mortality 
in Subjects With COPD. Respir Care, 2017. 62(5): p. 579-587. 
48. Schneider, L.P., et al., Sedentary Behaviour and Physical Inactivity in Patients with 
Chronic Obstructive Pulmonary Disease: Two Sides of the Same Coin? COPD, 2018. 
15(5): p. 432-438. 
49. Armstrong, M., et al., Use of pedometers as a tool to promote daily physical activity 
levels in patients with COPD: a systematic review and meta-analysis. Eur Respir Rev, 
2019. 28(154). 
50. de Mullenheim, P.Y., et al., Using GPS, accelerometry and heart rate to predict 
outdoor graded walking energy expenditure. J Sci Med Sport, 2018. 21(2): p. 166-
172. 
51. Regulation  (EU) 2017/745 of the European Parliament and of the council on medical 
devices. 2017; Available from: https://eur-lex.europa.eu/legal-
content/EN/TXT/PDF/?uri=CELEX:32017R0745. 




53. John, D., et al., "What Is a Step?" Differences in How a Step Is Detected among Three 
Popular Activity Monitors That Have Impacted Physical Activity Research. Sensors 
(Basel), 2018. 18(4). 
54. Use of Mobile Technologies in Clinical Research. CTTI’s recommendations: 
Advancing the Use of Mobile Technologies for 2 Data Capture & Improved Clinical 
Trials. 2018; Available from: https://www.ctti-clinicaltrials.org/sites/www.ctti-
clinicaltrials.org/files/mobile-devices-recommendations.pdf. 
55. Van Remoortel, H., et al., Validity of six activity monitors in chronic obstructive 
pulmonary disease: a comparison with indirect calorimetry. PLoS One, 2012. 7(6): p. 
e39198. 
56. Van Remoortel, H., et al., Validity of activity monitors in health and chronic disease: 
a systematic review. Int J Behav Nutr Phys Act, 2012. 9: p. 84. 
57. Moy, M.L., et al., Daily step counts in a US cohort with COPD. Respir Med, 2012. 
106(7): p. 962-9. 
58. Blondeel, A., et al., Accuracy of consumer-based activity trackers as measuring tool 
and coaching device in patients with COPD and healthy controls. . PLoS One, 2020. 
Accepted for publication. 
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
59. Gaz, D.V., et al., Determining the Validity and Accuracy of Multiple Activity-
Tracking Devices in Controlled and Free-Walking Conditions. Am J Health Promot, 
2018. 32(8): p. 1671-1678. 
60. Demeyer, H., et al., Standardizing the analysis of physical activity in patients with 
COPD following a pulmonary rehabilitation program. Chest, 2014. 146(2): p. 318-
327. 
61. Furlanetto, K.C., et al., Physical Activity of Patients with COPD from Regions with 
Different Climatic Variations. COPD, 2017. 14(3): p. 276-283. 
62. Mesquita, R., et al., Physical activity patterns and clusters in 1001 patients with 
COPD. Chron Respir Dis, 2017. 14(3): p. 256-269. 
63. Pitta, F., et al., Characteristics of physical activities in daily life in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med, 2005. 171(9): p. 972-7. 
64. Doherty, A., et al., Large Scale Population Assessment of Physical Activity Using 
Wrist Worn Accelerometers: The UK Biobank Study. PLoS One, 2017. 12(2): p. 
e0169649. 
65. Matthews, C.E., et al., Best practices for using physical activity monitors in 
population-based research. Med Sci Sports Exerc, 2012. 44(1 Suppl 1): p. S68-76. 
66. Byrom, B. and D.A. Rowe, Measuring free-living physical activity in COPD patients: 
Deriving methodology standards for clinical trials through a review of research 
studies. Contemp Clin Trials, 2016. 47: p. 172-84. 
67. Watz, H., et al., Physical activity in patients with COPD. Eur Respir J, 2009. 33(2): p. 
262-72. 
68. Orme, M.W., et al., Changes in physical activity during hospital admission for 
chronic respiratory disease. Respirology, 2019. 24(7): p. 652-657. 
69. Boutou, A.K., et al., Progression of physical inactivity in COPD patients: the effect of 
time and climate conditions - a multicenter prospective cohort study. Int J Chron 
Obstruct Pulmon Dis, 2019. 14: p. 1979-1992. 
70. Duenas-Espin, I., et al., Depression symptoms reduce physical activity in COPD 
patients: a prospective multicenter study. Int J Chron Obstruct Pulmon Dis, 2016. 11: 
p. 1287-95. 
71. Demeyer, H., et al., The Minimal Important Difference in Physical Activity in Patients 
with COPD. PLoS One, 2016. 11(4): p. e0154587. 
72. Teylan, M., et al., Physical activity in COPD: Minimal clinically important difference 
for medical events. Chron Respir Dis, 2019. 16: p. 1479973118816424. 
73. European Medicines Agency: Qualification of novel methodologies for medicine 
development. Last visited on 14/07/2020; Available from: 
https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-
advice-protocol-assistance/qualification-novel-methodologies-medicine-development. 
74. Food & Drug administration: Drug Development Tool Qualifcation Process: 
Transparency Provisions. 2019; Available from: https://www.fda.gov/drugs/drug-
development-tool-qualification-programs/drug-development-tool-qualification-
process-transparency-provisions. 
75. European Medicines Agency: Questions and anwsers: qualification of digital 




76. European Public Assessment Report about Eklira Genuair: product information. 
2019; Available from: https://www.ema.europa.eu/en/documents/product-
information/duaklir-genuair-epar-product-information_en.pdf. 
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
77. Garcia-Rio, F., et al., Prognostic value of the objective measurement of daily physical 
activity in patients with COPD. Chest, 2012. 142(2): p. 338-346. 
78. Waschki, B., et al., Disease Progression and Changes in Physical Activity in Patients 
with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 2015. 
192(3): p. 295-306. 
79. Ainsworth, B.E., et al., 2011 Compendium of Physical Activities: a second update of 
codes and MET values. Med Sci Sports Exerc, 2011. 43(8): p. 1575-81. 
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
Tables  
 
 Studied PA exposure  Impact on change 
Lung function  
Garcia-Rio, 
2012 [77] 
Baseline VMU Weak bivariable association (r=0.24) but PA 




Persistent inactivity (low 
PA at baseline and FU) 
based on PAL and steps 
No association (multivariable model) 
between PA and FEV1 decline. 
Demeyer, 2019 
[24] 
Baseline steps, MVPA, 
sedentary time 
PA is related (multivariable model) to 
attenuated decline in FEV1, FVC, DLCO. 
Functional capacity and strength 
Waschki, 2015 
[78] 
Persistent inactivity (low 
PA at baseline and FU) 
based on PAL and steps 
Faster decline in 6MWD and FFM in 




Baseline steps, MVPA, 
sedentary time 
PA is not related (multivariable model) to 
decline in 6MWD and HGF. 
Quality of life 
Demeyer, 2019 
[24] 
Baseline steps, MVPA, 
sedentary time 
PA is related (multivariable model) to the 
change in symptom domain of the SGRQ.  
Table 1: The association between physical activity and disease progression based on 
longitudinal studies using an objective PA assessment. PA= physical activity, VMU=vector 
magnitude units, PAL=physical activity level, FEV1= forced expiratory volume in 1 second, 
FVC = forced vital capacity, DLco = diffusion capacity of the lung for carbon monoxide, 
MVPA=time in moderate to vigorous intense physical activity, FU= follow up, 6MWD = six-
minutes walk distance, FFM= fat free mass, HGF = hand grip force, SGRQ = St Georges 
respiratory questionnaire. For more information on the different PA exposures, see section 
“dimensions of Physical Activity”.  
 
 
Cut-off Classification  
<5000 steps/day Sedentary  
5000 -7500 steps/day Low active 
7500-10000 steps/day Somewhat active 
10000-12500 steps/day Active 
≥12500 steps/day Very active 
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Cut-off Intensity  Examples 
1.5-3 METs Activities of light intensity Light effort household activities 
such as cooking, washing up, 
changing linen, dressing 
3-6 METs Activities of Moderate intensity Walking at moderate-brisk pace 
on a firm surface, mowing lawn 
≥6 METs Activities of Vigorous intensity Running, climbing hills 













Table 4. Factor analysis (principal components analysis) based on PA outcomes of valid days 
measured with the Dynaport Movemonitor at baseline of the Urban Training study [42]; 
Loadings of different PA variables are provided when >0.5 *sedentary time is a concept 

















Overall amount of 
PA 
Mean step count (steps/day) 0.78  
Walking time (min/day) 0.82  
Standing time (min/day) 0.86  
Active time (min/day) 0.96  
Intensity of the 
activity  
Walking intensity (m.s-2)  0.89 
VMU/min 0.52 0.64 
MVPA (min/day) 0.83  
Vigorous activity (min/day)  0.85 
Energy expenditure Active energy expenditure 0.70  
Sedentary 
behaviour 
Sedentary time* -0.75  
PRE-PROOF Chronic Obstructive Pulmonsry Diseases: Journal of the COPD Foundation PRE-PROOF 
 
Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation ©2021 
Published online August 25, 2021     doi: https://doi.org/10.15326/jcopdf.2021.0213   
Recommended standard operating procedure for data collection 
Sample interval Waking hours (for physical activity) or 24 hours 
Number and type of days Per protocol: 1 week 
Instructions to subjects Positioning, wearing period 
Log book Not mandatory: Period not worn, time out of bed, time in bed 
Post processing of data 
Definition of a valid day At least 8 hours of wear during waking hours. If 24 hours 
assessment is performed, at least 8 hours of wear in the 
timeframe between 7AM and 10PM or individual reported 
waking time.  
Week or weekend days Weekend and weekdays should be used to characterize the PA 
level of a patient. In a clinical trial (pre-post design) excluding 
weekend days can be considered to reduce variability. Days 
with a clinical visit at the study site should be excluded as it is 
not a normal assessment day. 
Number of valid days  Recommended 4 days (weekdays preferable). If in a minority 
of the study population at least 2 weekdays are available, this 
can still be acceptable to maintain the patient sample size. 
Covariates to consider Duration of daylight, definition and duration of wearing time 
Interpretation of data 
Data reduction Daily bins summarized as mean daily physical activity based 
on all valid (week)days 
Table 5: Recommendations for data collection, post processing and interpretation of 
objectively measured physical activity in stable patients with chronic respiratory disease; * 
More research is needed.  
 
 
 For steps/day as 
marker of general 
activity 
• Does the monitor measure what you want it to measure?  
• Does the CoU measure what is important to the patient?  
• Does the monitor/CoU do both of these in the specific population to 
be studied? 
 
• If there are multiple concepts / domains being measured (e.g. 
HRQOL), do they overlap? Are they weighted appropriately? 
n.a. 
• Is the CoU reliable? (e.g. stable in stable patients)   
• Is the CoU sensitive to baseline differences?   
• Is the CoU sufficiently sensitive to detect change over time?  
• Can it be used in multinational studies (multiple languages, cultures)  
Table 6: Colour codes:  in the opinion of the CBQC working group sufficient (green) or not 
sufficient (orange) evidence is available for the outcome steps per day; CoU = context of use 
(adapted from the 2014 EMA Qualification of novel methodologies for drug development: 
guidance to applicants)  
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Figure Captions 
Figure 1: End point model of physical activity. Factors influencing physical activity 
(behavioral end points) are based on the ecological model of Bauman et al. [8].  
Figure 2: Relation between mean total daily amount of PA irrespective of intensity (step count) 
and time in at least moderate intense activity (MVPA), based on a pooled sample of COPD 
patients recruited in UK (n=100), Spain (n=167), Germany (n=169), Belgium (n=173) and 
Brazil (n=67) with at least 4 valid days of assessment (1 week of PA assessment using the 
Sensewear armband) 
Figure 3 Consumer vs medical grade device. For each characteristic (e.g., cost), a colour 
indicates general favorability for a context of use with most devices in that category (i.e., 
consumer vs. medical grade), with green indicating good general favorability, yellow indicated 
that some devices within that category may meet required criteria, red indicates that most 
devices in that category are not favorable 
Figure 4: Physical activity pattern. Panel A shows the minute-by-minute mean METs level of 
patients included in UK (n=100), Spain (n=167), Germany (n=169), Belgium (n=173) and 
Brazil (n=67), based on 1 week of PA assessment using the Sensewear armband with at least 
4 valid days per patient; Panel B shows the cumulative proportion of the total daily step count 
taken on each minute of the day in these patients. 178 patients included in the COPDgene study 
(US) measured with Actigraph for mean (SD) 21 (3) days were added.  
Figure 5: Day-by-day physical activity (mean and SEM) in 151 COPD patients measured for 
21 consecutive days with Actigraph as part of the COPDgene study [4].  
Figure 6: Processing of data  
Figure 7: Recommended post-processing of data depending on the sample interval used.  *a 
minimum of 4 days is set as recommended number of days, 2 weekdays can be used as a 
minimal requirement.  
Figure 8: Physical activity on weekend (open bars) and weekdays (solid bars) of patients 
included UK (n=100), Spain (n=167), Germany (n=169), Belgium (n=173) and Brazil (n=67) 
with at least 4 valid days based on 1 week of PA assessment using the Sensewear armband. 
Data of COPDGene (US) are based on 178 patients, measured for 21 (3) days using the 
Actigraph. Data of different studies were pooled, resulting in different patient characteristics 
across countries. Mean (SD) FEV1 data are reported on top of each sample as a percentage of 
the predicted values, *significant difference based on paired t-test.  
Figure 9: Percentage of patients included in the analyses when using at least 2 to 7 days or 2 
to 5 weekdays both pre- and post-assessment to define a measure as valid. Recommended 
criterion (i.e., at least 4 days) and acceptable criterion in a minority of the population (i.e., at 
least 2 weekdays) are highlighted. Data are based on the multicentre PROactive study 
investigating a 3 month tele-coaching intervention using Actigraph data measured for 1 week 
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Figure 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
